Floatz logo

e7777

Cutaneous T-cell Lymphoma

Eisai Co., Ltd.Phase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

62 Active assets in the Cutaneous T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

e7777 is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
59 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
high grade B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →